Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Frontiers in Oncology|August 14, 2025
PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinibYingfang Feng, Yuan Gao, Shaochuan Liu, et al.Cancer Medicine|June 23, 2023
Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinibYuan Gao, Yingfang Feng, Shaochuan Liu, et al.Cell Death & Disease|May 6, 2020
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cellsShaochuan Liu, Tingting Qin, Zhujun Liu, et al.Expert Opinion on Biological Therapy|December 20, 2024
An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphomaYingfang Feng, Xia Liu, Jingwei Yu, et al.European Journal of Cancer (Oxford, England : 1990)|November 3, 2024
Elevated serum magnesium levels prompt favourable outcomes in cancer patients treated with immune checkpoint blockersYingfang Feng, Meng Gao, Xiyue Xu, et al.Frontiers in Immunology|December 29, 2025
Single-cell and bulk transcriptomics reveal a CD8<sup>+</sup> T-cell gene signature predicting prognosis in diffuse large B-cell lymphomaHengqi Liu, Yingfang Feng, Zhengzi Qian, et al.Cancer Research|April 18, 2024
CD58 Alterations Govern Antitumor Immune Responses by Inducing PDL1 and IDO in Diffuse Large B-Cell LymphomaXiyue Xu, Yidan Zhang, Yaxiao Lu, et al.Pageof 1